[go: up one dir, main page]

PE20090999A1 - Nuevos derivados de metil-bencimidazol - Google Patents

Nuevos derivados de metil-bencimidazol

Info

Publication number
PE20090999A1
PE20090999A1 PE2008001917A PE2008001917A PE20090999A1 PE 20090999 A1 PE20090999 A1 PE 20090999A1 PE 2008001917 A PE2008001917 A PE 2008001917A PE 2008001917 A PE2008001917 A PE 2008001917A PE 20090999 A1 PE20090999 A1 PE 20090999A1
Authority
PE
Peru
Prior art keywords
cycloalkyl
alkyl
difluor
benzoimidazol
acetamide
Prior art date
Application number
PE2008001917A
Other languages
English (en)
Inventor
Gregory Martin Benson
Konrad Bleicher
Uwe Grether
Rainer E Martin
Jean-Marc Plancher
Hans Richter
Sven Taylor
Minmin Yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20090999A1 publication Critical patent/PE20090999A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE METIL-BENCIMIDAZOL DE FORMULA (I) DONDE R1 ES CICLOALQUILO(C3-C10), ALQUILO(C1-C7) INFERIOR, ARILO, ENTRE OTROS; R2 ES H O ALQUILO(C1-C7) INFERIOR; R3 ES CICLOALQUILO(C3-C10), ALQUILO(C1-C7) INFERIOR, CICLOALQUIL(C3-C10)-ALQUILO(C1-C7) INFERIOR, ENTRE OTROS; R4 ES ARILO, CICLOALQUILO(C3-C10), HETEROARILO, ENTRE OTROS; R5 Y R6 SON CADA UNO H, HIDROXI, ALCOXI(C1-C7) INFERIOR, ENTRE OTROS; R7, R8, R9 Y R10 SON CADA UNO H, HALOGENO, HIDROXI, ALQUILO(C1-C7) INFERIOR, ALCOXI(C1-C7) INFERIOR, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-[2-(3-CLORO-BENCIL)-5,6-DIFLUOR-BENZOIMIDAZOL-1-IL]-2,N-DICICLOHEXIL-ACETAMIDA, 2,N-DICICLOHEXIL-2-[5,6-DIFLUOR-2-(4-ISOPROPIL-BENCIL)-BENZOIMIDAZOL-1-IL]-ACETAMIDA, 2,N-DICICLOHEXIL-2-[2-(4-ETOXI-BENCIL)-5,6-DIFLUOR-BENZOIMIDAZOL-1-IL]-ACETAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCESO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL RECEPTOR X DE FARNESOIDE (FXR) SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDAD ATEROSCLEROTICA, DIABETES MELLITUS, SINDROME METABOLICO, OBESIDAD
PE2008001917A 2007-11-15 2008-11-12 Nuevos derivados de metil-bencimidazol PE20090999A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07120737 2007-11-15

Publications (1)

Publication Number Publication Date
PE20090999A1 true PE20090999A1 (es) 2009-07-20

Family

ID=40551982

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001917A PE20090999A1 (es) 2007-11-15 2008-11-12 Nuevos derivados de metil-bencimidazol

Country Status (16)

Country Link
US (2) US7825258B2 (es)
EP (1) EP2222645B1 (es)
JP (1) JP5222953B2 (es)
KR (1) KR101176721B1 (es)
CN (1) CN101855214B (es)
AR (1) AR069306A1 (es)
AU (1) AU2008323017B2 (es)
BR (1) BRPI0818813A2 (es)
CA (1) CA2704074A1 (es)
CL (1) CL2008003372A1 (es)
ES (1) ES2403592T3 (es)
IL (1) IL205207A0 (es)
MX (1) MX2010005164A (es)
PE (1) PE20090999A1 (es)
TW (1) TW200924755A (es)
WO (1) WO2009062874A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028981A1 (en) * 2008-09-11 2010-03-18 F. Hoffmann-La Roche Ag New benzimidazole derivatives
EP2350022B1 (en) * 2008-10-15 2013-11-20 F. Hoffmann-La Roche AG New benzimidazole derivatives
US8309581B2 (en) * 2009-09-29 2012-11-13 Hoffmann-La Roche Inc. Benzimidazole derivatives
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
ES2822375T3 (es) * 2012-06-19 2021-04-30 Intercept Pharmaceuticals Inc Preparación de la forma no cristalina del ácido obeticólico
LT3043865T (lt) 2013-09-11 2021-04-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Hepatito b viruso infekcijos gydymo būdai ir farmacinė kompozicija
CA3051776A1 (en) 2017-02-21 2018-08-30 Genfit Combination of a ppar and fxr agonist for the treatment of liver disorders
EP3600293A1 (en) 2017-03-30 2020-02-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
WO2021188690A1 (en) * 2020-03-18 2021-09-23 Metacrine, Inc. Farnesoid x receptor agonists for the treatment of disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU741946B2 (en) * 1998-07-20 2001-12-13 Bristol-Myers Squibb Company Substituted benzimidazole antiviral agents
JP4656838B2 (ja) 2002-02-06 2011-03-23 バーテックス ファーマシューティカルズ インコーポレイテッド Ｇｓｋ−３の阻害剤として有用なヘテロアリール化合物
CA2530081A1 (en) * 2003-07-01 2005-01-13 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
RU2424233C2 (ru) * 2006-06-29 2011-07-20 Ф.Хоффманн-Ля Рош Аг Производные бензимидазола, методы их получения, применение их в качестве агонистов фарнезоид-х-рецептора (fxr) и содержащие их фармацевтические препараты
JP5204232B2 (ja) * 2007-08-27 2013-06-05 エフ．ホフマン−ラ ロシュ アーゲー Ｆｘｒアゴニストとして使用されるベンゾイミダゾール誘導体

Also Published As

Publication number Publication date
US20090131482A1 (en) 2009-05-21
ES2403592T3 (es) 2013-05-20
EP2222645A2 (en) 2010-09-01
WO2009062874A3 (en) 2009-07-09
KR20100071102A (ko) 2010-06-28
US8008503B2 (en) 2011-08-30
AU2008323017A1 (en) 2009-05-22
US7825258B2 (en) 2010-11-02
JP5222953B2 (ja) 2013-06-26
CN101855214B (zh) 2012-12-26
US20100331371A1 (en) 2010-12-30
AU2008323017B2 (en) 2012-12-20
TW200924755A (en) 2009-06-16
IL205207A0 (en) 2010-12-30
KR101176721B1 (ko) 2012-08-23
JP2011503136A (ja) 2011-01-27
CA2704074A1 (en) 2009-05-22
BRPI0818813A2 (pt) 2015-04-22
WO2009062874A2 (en) 2009-05-22
AR069306A1 (es) 2010-01-13
CL2008003372A1 (es) 2010-01-04
MX2010005164A (es) 2010-05-27
EP2222645B1 (en) 2013-03-20
CN101855214A (zh) 2010-10-06

Similar Documents

Publication Publication Date Title
PE20090999A1 (es) Nuevos derivados de metil-bencimidazol
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
PE20141375A1 (es) Activadores de glucoquinasa
PE20120790A1 (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
PE20080056A1 (es) Derivados de cromencarboxamida como antagonistas del receptor s1p1
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20080065A1 (es) Compuestos derivados de bencimidazol como moduladores del receptor vainilloide vr1
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20110684A1 (es) Agonistas de los receptores de la melanocortina
PE20091204A1 (es) Derivados de 2-aminoquinolina como antagonistas del receptor de 5-ht5a
PE20090482A1 (es) Derivados heterociclicos como antagonistas del receptor ccr2
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace
PE20121640A1 (es) Derivados de pirazina como inhibidores de bace
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
PE20080543A1 (es) Nuevos derivados de fenilo, piridina y quinolina
PE20121058A1 (es) Compuestos que modulan el receptor de androgenos
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20090741A1 (es) Derivados de 1,1,1-trifluor-2-hidroxi-3-fenilpropano
PE20081404A1 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona y procesos para su preparacion
PE20080697A1 (es) Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20110237A1 (es) Derivados de ciclohexilamida como antagonistas del receptor del factor de liberacion de corticotropina (crf-1)
PE20080278A1 (es) Compuestos de benzimidazolilo
PE20090297A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal